The German patch and oral-film maker announces the opening of its own business development office in the US, targeting the biggest pharmaceutical market globally while improving customer focus.
tesa Labtec offers the development and manufacture of film-shaped dosage forms (CDMO services) like transdermal and topical patches as well as buccal or sublingual films. The business activities comprise formulation development, scale-up, and manufacture of clinical trial supplies or finished products under full cGMP conditions. tesa can count on its proprietary technologies Transfilm®, Rapidfilm®, and Mucofilm® for this.
By opening its own business development office, tesa is taking the next step for the internationalization of its business within its customer-centric growth strategy. Until now tesa has been offering its services mainly to German and European customers and intends to break into the biggest pharmaceutical market globally now. US customers can benefit from an improved service offering better accessibility and faster feedback on their inquiries.
Dr. Ingo Lehrke, Managing Director, emphasizes: “We are enthusiastic about the opportunity to expand our business and services to the biggest pharmaceutical market globally. With the establishment of our local business development office we are reacting to the increased number of service inquiries for the US market. This measure constitutes the next step to build tesa’s name as a preferred provider for the development and manufacture of patches and oral soluble films in the US.”
The new US office is located in Charlotte, North Carolina. Further information, contact details, and contact persons can be found under "Contact".